Kips Bay Medical Provides Clinical Trial Update and Reports First Quarter 2015 Results
GlobeNewswire - Tue May 12, 3:53PM CDT
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today provided a clinical trial update and announced financial results for its first quarter ended March 28, 2015.
Sell Great Basin Scientific Inc., Penny Stock Newsletter Pumps Don't End Well
Big Banks - at Seeking Alpha - Mon Apr 06, 2:31PM CDT
GNMK: 9.40 (-0.02), GBSN: 3.29 (+0.07), RCAP: 7.83 (-0.13), QDEL: 23.05 (+0.03), CPHD: 57.71 (-0.39), RTGN: 4.04 (+0.02)
Kips Bay Medical Announces $3.25 Million Private Placement Bridge Financing
GlobeNewswire - Tue Mar 24, 3:37PM CDT
Investors Include Manny Villafana and Kips Bay Investments, LLC
Kips Bay Medical Announces Achievement of Enrollment Goal and Provides Business Update and Fourth Quarter and Full Year 2014 Results
GlobeNewswire - Thu Mar 12, 8:09AM CDT
Manny Villafana, Chairman and Chief Executive Officer of Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting surgery, today announced that the Company had reached its targeted enrollment goal for its eMESH I clinical feasibility trial and provided a business update and financial results for its fourth quarter and full year ended December 31, 2014.
Kips Bay Medical retrenches to focus on vein graft product
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 12:15PM CST
Kips Bay Medical Reorganizes Operations and Reduces Staff to Focus on Clinical Study Work and Conserve Capital
GlobeNewswire - Mon Jan 05, 11:00AM CST
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that the Company has reorganized its operations by eliminating staff positions, instituting salary reductions and reducing its non-clinical related operating expenses, in order to conserve its capital while it pursues the completion of its current eMESH I clinical feasibility trial.
Kips Bay Medical Announces the First eSVS Mesh Implant by the Valley Hospital of New Jersey
GlobeNewswire - Tue Nov 11, 8:23AM CST
Manny Villafana, Chairman and CEO of Kips Bay Medical, Inc. (OTCQB:KIPS), announced that on November 4, 2014, cardiac surgeons at The Valley Hospital's Heart and Vascular Institute in Ridgewood, New Jersey, performed their first implant of an eSVS Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.
Kips Bay Medical Provides Feasibility Study Update and Reports Third Quarter 2014 Results
GlobeNewswire - Thu Nov 06, 8:45AM CST
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its third quarter ended September 27, 2014.
Kips Bay Medical Q3 EPS of -$0.04
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:26AM CST
Kips Bay Medical Provides Clinical and Business Update
GlobeNewswire - Tue Oct 14, 8:00AM CDT
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provides an update on its clinical progress and business operations.
Kips Bay Medical Announces Trading on OTCQB Marketplace
GlobeNewswire - Mon Sep 15, 9:05AM CDT
Kips Bay Medical, Inc. (OTCQB:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that its common stock began trading on the OTCQB Marketplace on September 12, 2014.
Kips Bay Medical Receives Updated CE Mark Approval
GlobeNewswire - Mon Aug 25, 8:00AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today announced that it has received an updated CE Mark approving use of a new surgical implant technique for its eSVS Mesh.
Kips Bay Medical Provides Feasibility Study Update and Reports Second Quarter 2014 Results
GlobeNewswire - Tue Aug 12, 8:05AM CDT
Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its second quarter ended June 28, 2014.
Kips Bay Medical Announces the First eSVS Mesh Implant by Lenox Hill Hospital of New York
GlobeNewswire - Mon Jul 28, 8:03AM CDT
Manny Villafana, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on July 17, 2014, Lenox Hill Hospital in New York City performed its first implant of an eSVS(R) Mesh. This implant was performed as part of the Kips Bay Medical eMESH I clinical feasibility trial currently being conducted for the U.S. Food and Drug Administration (FDA) in a number of preeminent cardiac surgery centers in both Europe and the United States.
Nasdaq stocks posting largest volume increases
AP - Thu Jul 03, 4:16PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LSBK: 13.63 (+0.13), VBFC: 19.75 (+0.15), ISLE: 14.30 (+0.14), CBAK: 3.64 (+0.04), SHIP: 0.71 (-0.01), CHNR: 2.10 (+0.05), VRTA: 4.15 (+0.63), ONFC: 19.70 (-0.05)